Form 4: Lexeo CMO Sells Shares for Tax Obligations

Lexeo Therapeutics' Chief Medical Officer, Eric Adler, sold 615 shares of common stock on November 18, 2025, to cover tax obligations related to restricted stock units.

Summary

• Eric Adler, Chief Medical Officer of Lexeo Therapeutics, Inc. (LXEO), reported a sale of common stock.
• The transaction occurred on November 18, 2025.
• 615 shares of common stock were disposed of.
• The weighted average sale price was $9.27 per share, with trades ranging from $9.09 to $9.37.
• The sale was executed to cover tax obligations arising from the release of restricted stock units (RSUs).
• Following this transaction, Eric Adler beneficially owns 72,646 shares, which includes 58,866 RSUs.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale to cover tax obligations on restricted stock units, which is a neutral event. It does not indicate a change in company fundamentals or management's confidence beyond standard equity management.

Positives

• The sale was pre-planned under a Rule 10b5-1(c) plan, indicating a structured approach to managing equity and tax obligations rather than an opportunistic sale based on new information.

Negatives

• A reduction in direct share ownership by a key executive, even for tax purposes, slightly decreases their direct equity alignment with shareholders.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide broader industry context. Such sales are common for executives managing their equity compensation.

Stakeholder Impact

• Minimal direct impact on shareholders as it's a small, routine, tax-related sale by an executive.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned sale of a small number of shares by a Chief Medical Officer to cover tax obligations related to restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

Lexeo Therapeutics, LXEO, Eric Adler, Chief Medical Officer, Insider Trading, Form 4, Stock Sale, Tax Obligations, Restricted Stock Units, RSUs, 10b5-1 Plan